GMT EIGHT - Company

China Vanke Co., Ltd. hits the limit up during trading, with multiple bonds rising significantly in recent days.

Today, the leading stock price of real estate companies surged, with A-shares rising limit up in early trading and closing up 7.45%. At the same time, several bonds of Vanke continued to surge, with "22 Vanke 05" rising more than 30%, triggering a second intraday trading halt. "22 Vanke 07", "20 Vanke 08", and "21 Vanke 02" all rose more than 20%, triggering intraday trading halts. Yesterday afternoon, three bonds of Vanke surged more than 20% triggering trading halts. "22 Vanke 07" rose 24.2%, "22 Vanke 05" rose 20.01%, and "22 Vanke 02" rose 20%; ultimately, "22 Vanke 07" closed up 22% and "22 Vanke 02" rose over 16%. Today, "22 Vanke 04" surged 20% and temporarily halted trading. Last night, Vanke issued a notice for the payment of interest on a special company bond for housing leasing in 2025, which showed that the coupon rate for "21 Vanke 02" was 3.98%. In this interest payment plan, each bond (face value of 1000 yuan) will receive 39.80 yuan in interest (including tax), which is seen as a positive signal for Vanke's stable development. According to third-party statistics, Vanke's real estate business sales amount exceeded 240 billion yuan in 2024, ranking at the top, and having the highest sales area nationwide. According to Vanke's quarterly report released earlier, the company continued to adhere to its financial safety line with efforts from all sides. In the third quarter of last year, Vanke maintained positive operating cash flow, with a repayment amount exceeding 180 billion yuan from January to September, a repayment rate of over 100%; the debt structure continued to be optimized, with the weighted average debt maturity extended to 5.4 years. Vanke also continued to receive active support from financial institutions, achieving new and refinancing over 77 billion yuan, operating property loans exceeding 25 billion, while maintaining low financing costs, with a comprehensive cost of new financing at 3.58%, further decreased from the mid-term; in addition, Vanke actively promoted bulk asset transactions, with contract amounts exceeding 20 billion in the first three quarters. Through full efforts, Vanke continued to reduce its stock debt, with interest-bearing liabilities repaid by about 70 billion from January to September, and no public debt both domestically and internationally in 2024. At the same time, in the first three quarters, Vanke delivered over 110,000 units to customers as scheduled, continuing to improve delivery quality and living experience, completing community facilities in 51 major projects, promoting community atmospheres, and adding over 20,000 households to the residents. In order to ensure that consumers can live in their new homes with peace of mind, "delivery and certificate processing" has been promoted during the delivery phase, allowing owners of hundreds of projects to receive their property certificates on-site. Regarding the performance of the real estate market in various cities, the National Bureau of Statistics recently stated that in December 2024, among 70 large and medium-sized cities, the selling prices of residential properties in first-tier cities rose month-on-month, while the overall decline in prices in second and third-tier cities narrowed. The year-on-year decline in prices in first, second, and third-tier cities all continued to narrow. From the data for December 2024, sales amount and sales area increased by 2.8% and 0.4% respectively year-on-year. The Bureau of Statistics stated that the real estate market has seen positive changes under the influence of a combination of policies, and market confidence is gradually being restored. With the effective implementation of existing policies and incremental policies, the real estate market is expected to continue to improve in the next phase. In the medium to long term, China's new urbanization has not been completed, and the demand for first-time and upgraded housing still has potential. The demand for more safe, comfortable, green, and smart homes will increase, and new models of real estate market development will gradually be established, which will contribute to the stable and healthy development of the real estate market.

21/01/2025

"Science enthusiasts for beauty, good news! MaiLi Extreme has been approved domestically, Huadong Medicine (000963.SZ) makes a new breakthrough in the high-end medical beauty market."

On January 20, 2025, Huadong Medicine Co., Ltd. (000963.SZ) announced that its wholly-owned subsidiary Xin Ke Li Mei Xue (Shanghai) Medical Technology Co., Ltd. (hereinafter referred to as "Xinke Li Mei Xue Shanghai") has received the "Medical Device Registration Certificate" issued by the National Medical Products Administration (NMPA) for three types of medical devices it applied for on behalf of, including the MaiLi Extreme cross-linked hyaluronic acid sodium gel containing lidocaine for injection, and has obtained approval for listing. It is reported that the MaiLi series consists of four products, including MaiLi Precise, MaiLi Define, MaiLi Volume, and MaiLi Extreme, all of which have been launched in Europe and can be used for different parts of the face, providing a comprehensive solution for facial beauty filling for those seeking beauty. Using the OxiFree patented technology to innovate the high-end medical aesthetics filling market The announcement stated that Sinclair, a wholly-owned subsidiary of Huadong Medicine in the UK, holds the exclusive global license for the MaiLi series products. The MaiLi series products contain lidocaine, which can reduce the pain during the injection process. The innovative OxiFree patented technology used in these products can reduce the amount of cross-linking agent used, prolong the maintenance time, have excellent rheological properties, especially better filling ability, reduce the amount of product injected, and provide lasting filling effects. As the product with the highest hyaluronic acid concentration and the strongest volumizing ability in the MaiLi series products, MaiLi Extreme can instantly fill and shape after injection, rapidly improving the jaw contour of patients with retruded jaw. This product has undergone and completed a prospective, multicenter, randomized, non-therapeutic controlled, evaluator-blind, superiority clinical trial in China to evaluate the effectiveness and safety of cross-linked hyaluronic acid sodium gel containing lidocaine for chin filling, showing good filling performance and safety. The MaiLi series products mainly target the high-end market, aiming to fill the gap in the demand for high-end medical aesthetics in China. According to the blue book "Current Development Status and Future Trends of Medical Aesthetic Injection Products" published by Frost & Sullivan, non-surgical medical aesthetic projects represented by injection and photonics are more widely accepted by consumers due to their low invasiveness and quick recovery characteristics. Among them, injection projects have the advantages of strong shaping ability and visible effects, and are widely favored by the market. According to the global statistics released by The International Society of Plastic Surgery (ISAPS), hyaluronic acid is one of the most widely used and most frequently applied materials in non-surgical medical aesthetic injection projects. The global number of plastic surgeons performing hyaluronic acid injections reached 5.56 million procedures in 2023, accounting for 29.0% of all non-surgical medical aesthetic projects, with a year-on-year growth of 29.1%. According to BOC International's calculations, China's hyaluronic acid injection market is expected to reach a size of 46.6 billion yuan in 2025, with a penetration rate increasing from 1.28% in 2021 to 2.28% in 2025. This product obtained the EU CE certification in June 2020 and was launched in the European market in the first half of 2021, receiving positive feedback. In July 2024, the MaiLi series products were successfully launched in Singapore, actively exploring new markets. Therefore, the MaiLi series products have accumulated rich experience in the international market, and this approval for listing of MaiLi Extreme in China is expected to bring more facial filling solutions to beauty seekers in China. In addition, the new high-end lidocaine hyaluronic acid product MaiLi Precise completed the enrollment of all subjects in China's clinical trial on April 30, 2024. The study aimed to evaluate the effectiveness and safety of injecting MaiLi Precise in the subdermal region of the lower eyelids to correct the hollowing of the lower eyelids. MaiLi Precise is the lowest concentration of hyaluronic acid sodium in the MaiLi series, with a smaller G'(Elastic Modulus), making it more suitable for filling injections in the lower eyelids to achieve instant filling and shaping effects, rapidly improving the hollowing of the lower eyelids. Huadong Medicine expands its medical aesthetics territory further, creating a one-stop facial aesthetic solution Huadong Medicine continues to layout in the field of medical aesthetics, enriching its pipeline of injection products to provide beauty seekers with a one-stop facial complete aesthetic solution. As of now, in the field of injectable fillers, in addition to the MaiLi series, Huadong Medicine owns several important products, including Ellans and Lanluma V-shaped and X-shaped regenerative fillers, botulinum toxin product YY001, achieving full coverage of the regenerative, hyaluronic acid, and botulinum toxin categories, with two or more differentiated product pipelines in each category. Ellans is one of the core products of Huadong Medicine's medical aesthetics, and its clinical layout in China is progressing smoothly. Ellans has been dubbed "the juvenile needle" for its excellent triple effect of "instant filling, long-lasting maintenance, and natural metabolism." Ellans S-type has been launched in China, being the first imported PCL high-end facial filler approved as a third-class medical device in China, and added the indication of "improving forehead contour through forehead filling" in November 2024, completing the enrollment of all subjects. Ellans M-type completed the 18-month safety follow-up in China in October 2024. Huadong Medicine's another regenerative medical aesthetic filler, Lanluma, a polylactic acid collagen stimulant.Clinical trials are also progressing rapidly. In November 2024, all subjects have been enrolled in the clinical trial of Lanluma V for improving lower jaw contour defects. Lanluma is currently the only regenerative product approved for filling in the buttocks and thighs, with CE certification in the EU obtained in 2020. So far, it has been approved for sale in 32 countries and regions worldwide.In addition, Huadong Medicine's exclusive distributor product YY001, a recombinant type A botulinum toxin for injection, used to improve moderate to severe glabellar lines, received market approval on December 31, 2024 and was accepted by the National Medical Products Administration. It is worth mentioning that YY001 is the world's first and currently the only recombinant type A botulinum toxin product that has submitted a market application. Huadong Medicine continues to advance its clinical layout of injectable filler pipelines internationally, accelerating the globalization of high-end medical aesthetics. The company's new patent ingredient dermal filler KIO021 has started clinical trials in China. KIO021 has the same ingredients as KIO015 but with different specifications. KIO015 submitted a CE certification application to the European Union in July 2024, and is expected to obtain EU CE-MDR certification in 2025. Huadong Medicine stated that KIO015 is expected to become the world's first non-animal source chitosan medical aesthetic filler. Looking at the overall product pipeline layout, Huadong Medicine has achieved full coverage of the high-end market in non-surgical medical aesthetic injection products and energy source devices globally. The product portfolio covers mainstream non-surgical medical aesthetic areas such as improving glabellar lines, facial and body fillers, thread lifting, skin management, body shaping, hair removal, intimate repairs, and more. Huadong Medicine's medical aesthetic business upholds the strategy of "global operation layout, dual-cycle business development". With an international perspective, and through forward-looking layouts, it has built a comprehensive and differentiated product matrix. The number and coverage of products both rank at the forefront of the industry, with over twenty products already on the market domestically and internationally, and more than ten global innovative products under development. By integrating diverse joint treatment methods such as "non-invasive + minimally invasive", "facial + body", "product + technology", and "injection + energy source equipment", it provides a more professional, safe, efficient, and comprehensive solution for beauty seekers, striving to be a leading provider of comprehensive medical aesthetic solutions globally. Looking ahead, Huadong Medicine will continue to focus on the global high-end medical aesthetic market with a more open and forward-looking approach, continuously improving its product pipeline, and forming an international medical aesthetic business system that integrates research and development, manufacturing, and marketing. Leveraging the global operating platform of its core subsidiary Sinclair, the company will integrate technological innovation resources to achieve global operations in medical aesthetics, continuously introducing high-tech and high-potential "medical aesthetics + beauty" products into the Chinese market, and accelerating the landing and commercialization process of international high-quality medical aesthetic products. It aims to provide a more diverse and personalized medical aesthetic service for beauty seekers worldwide.

20/01/2025

Respiratory disease testing market size exceeds 40 billion yuan, MGI Tech Co., Ltd. (688114.SH) provides influenza monitoring equipment to various disease control centers.

Recently, there has been a high incidence of flu in many parts of the country. According to the latest data from the Chinese Center for Disease Control and Prevention, the positivity rate for flu viruses is continuously increasing. The annual spread of flu viruses has also become a key application scenario for genetic sequencing equipment. According to calculations by relevant agencies, from 2019 to 2023, the market size of the respiratory disease testing industry will increase from 78.21 billion yuan to 120.96 billion yuan, with a compound annual growth rate of 11.52% during this period. The agency predicts that from 2024 to 2028, the market size of the respiratory disease testing industry will increase from 148.69 billion yuan to 404.81 billion yuan, with a compound annual growth rate of 28.45%. In the prevention and control of flu viruses, high-throughput genetic sequencing technology plays a crucial role. It can quickly provide early warnings for novel flu viruses, optimize flu vaccine deployment strategies, and provide key insights into monitoring flu trends. MGI Tech Co., Ltd. (688114.SH) has developed a combination of respiratory microbiome genome sequencing products with its deep high-throughput sequencing technology. The MGIEasy Respiratory Microbiome Genome Library Preparation Reagent Kit, paired with MGI Tech Co., Ltd.'s DNBSEQ sequencer platforms of different throughputs, and the MGI FluTrack basic analysis system loaded on the MGI Tech Co., Ltd. bioinformatics accelerator module MegaBOLT server, can accurately identify the subtype of flu virus in samples and obtain complete flu virus genome sequences. This product combination provides efficient and rapid flu virus tracking and tracing tools for disease control departments and research institutions. Additionally, real-time monitoring and dynamic analysis of the full genome sequences of flu viruses can more accurately capture the development trends of flu outbreaks, issue timely warnings of new or highly pathogenic variants, and formulate more scientific and precise prevention and control strategies. Currently, disease control centers in many parts of the country have begun to use MGI Tech Co., Ltd.'s respiratory microbiome genome sequencing product combination to strengthen monitoring and research on the flu. For example, disease control centers in cities such as Tongling, Ma'anshan, Bozhou, and Xuancheng in Anhui Province have deployed flu virus sequencing work using MGI Tech Co., Ltd.'s respiratory microbiome genome sequencing product combination. Respiratory disease testing is becoming a normalized demand and experiencing ultra-high-speed growth. With the increasing demand for sequencing instruments from disease control departments and research institutions, as well as the entry of downstream manufacturers, companies that master core technologies and achieve integration of reagents and instruments can often generate higher product added value and obtain greater profits in the market competition.

13/01/2025

Manipulating the hot topic of "computing power" to control the pace of information disclosure! Jiangyin Hengrun Heavy Industries (603985.SH) former chairman Cheng Lixin and others were fined 140 million for manipulating stock prices.

The China Securities Regulatory Commission (CSRC) disclosed an administrative penalty decision today, in which Jiangyin Hengrun Heavy Industries (603985.SH) former chairman Cheng Lixin, as well as Ding Jian and Zhang Yazhou conspired to manipulate the stock price of Jiangyin Hengrun Heavy Industries. They were fined over 140 million yuan by the CSRC and were also imposed with a ban from entering the securities market. According to the CSRC investigation, Cheng Lixin, the then second-largest shareholder and legal representative and chairman of Jiangyin Hengrun Heavy Industries, conspired with Ding Jian and Zhang Yazhou to manipulate the stock price in mid-June 2023. Through Ding Jian's introduction, Cheng Lixin and Zhang Yazhou met, and the three of them conspired to hype the "mining power" hot topic by controlling the content, timing, and rhythm of information generation and disclosure. In actual operation, Cheng Lixin held "Jiangyin Hengrun Heavy Industries" stock in the name of others. Cheng Lixin planned to sell the "Jiangyin Hengrun Heavy Industries" stock in 2023 and signed a "Trust Agreement" with Ruan on July 16, 2023, for the private placement product to take over 24,952,563 shares of "Jiangyin Hengrun Heavy Industries". Subsequently, from July 29 to November 8, 2023, Cheng Lixin, Ding Jian, Zhang Yazhou, and others manipulated the company to release four pieces of positive information, boosting the stock price of "Jiangyin Hengrun Heavy Industries". During the aforementioned period, the stock price of "Jiangyin Hengrun Heavy Industries" rose by 96.65%, while the Shanghai Composite Index fell by 6.86%, deviating by 103.51%, and the Wind Power Industry Index fell by 10.30%, deviating by 106.95%. The increase in the stock price of "Jiangyin Hengrun Heavy Industries" was significantly higher than that of the Shanghai Composite Index and the industry index during the same period. This penalty decision detailed the information release situation of Cheng Lixin, Ding Jian, and Zhang Yazhou: 1. Failure to truthfully and completely disclose the establishment of the mining power subsidiary company On July 29, 2023, Jiangyin Hengrun Heavy Industries issued an announcement to establish a subsidiary, Shanghai Run Liushi Technology Co., Ltd. (referred to as Shanghai Run Liushi). Following an investigation, apart from the joint venture operations contract, Cheng Lixin and Zhang Yazhou also signed an agreement, while Jiangyin Hengrun Heavy Industries did not fully and accurately disclose the agreement. 2. Failure to truthfully and accurately disclose the situation of the subsidiary's equity acquisition agreement On September 26, 2023, Jiangyin Hengrun Heavy Industries issued a... Buy at a low price to boost stocks and maintain its value. During this period, the account group made a profit of 20,523,277.70 yuan.The China Securities Regulatory Commission (CSRC) has determined that Three's engaged in market manipulation in violation of the Securities Law. Although the three individuals presented arguments against being punished, such as the absence of "collusion" and the authenticity of the computing power business, these arguments were not accepted. The CSRC has decided to order the three individuals to dispose of the illegally held securities in accordance with the law, confiscate illegal gains of 20,523,277.7 yuan from Ding Jian, and impose fines totaling 123,139,666.2 yuan, which are to be borne by Cheng Lixin, Ding Jian, and Zhang Yazhou respectively. Additionally, considering the seriousness of their illegal behavior, Cheng Lixin and Ding Jian are subject to an 8-year ban from the securities market, while Zhang Yazhou is subject to a 3-year ban. During the ban period, they are prohibited from engaging in securities business, securities services, or holding positions as directors, supervisors, or senior managers of the original issuer, either at the original organization or any other institution. Due to the serious impact of Cheng Lixin and Ding Jian's illegal behavior on securities trading order, the CSRC has imposed a 5-year ban on them from the securities market. During the ban period, except for the circumstances specified in Article 6, paragraph 1 of the Securities Market Ban Regulations, they are prohibited from directly or indirectly trading in all securities listed or listed on the exchange under a pseudonym or in the name of another person. This article is a reprint from "Cailianshe". Edited by GMTEight: Chen Xiaoyi.

10/01/2025

Junwei Electronics (301458.SZ) successfully listed on the Growth Enterprise Board with the assistance of Huatai United Securities, promoting the development of leading domestic precision resistor and fuse companies.

On January 10th, Junwei Electronics (301458.SZ) was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange. The offering raised a total of 693 million RMB, with Huatai United Securities acting as the exclusive sponsor and lead underwriter. Junwei Electronics is primarily engaged in the design, research and development, manufacturing, and sales of precision resistors for current sensing and fuses. The company focuses on the research, production, and sales of precision resistors for current sensing and chip-type surface mount fuse products; its wholly-owned subsidiary, Suzhou Huade, was established in 2000 and has been dedicated to the research, production, and sales of fuse products since its establishment. The company's main customer base is diverse, covering enterprises in various fields such as smart phone terminals, computer terminals, household appliances, batteries, PD fast charging, power supplies, and industrial applications. In terms of precision resistors for current sensing, Junwei Electronics has grown to become a leading enterprise in China's precision resistor industry. According to QY Research and the company's revenue data for precision resistors for current sensing, by 2023, the company ranks third in the global market with a market share of 7.86%; the company is able to provide precision resistors for current sensing ranging from miniature to 0201 size (in inches), as thin as 0.33 mm, with high precision up to 5 and resistance values less than 1 milliohm. In the field of fuses, the global market is currently dominated by overseas enterprises; according to Paumanok Publications Inc. and Open Source Securities research on the global fuse market size and the company's fuse revenue data, by 2023, the company's market share in the global fuse market is 0.92%. As the exclusive sponsor and lead underwriter for Junwei Electronics' IPO, Huatai United Securities, based on a profound understanding of the high-tech manufacturing industry of electronic components, fully exploits Junwei Electronics' technological highlights and enterprise value, supporting Junwei Electronics' growth and successful listing on the Growth Enterprise Market. With the high degree of integration between industrialization and informatization, the application of electronic components has permeated the entire industrial field, supporting the foundation and key to the innovation and development of the entire industry. Junwei Electronics adheres to independent research and development, striving to become a global leader in providing solutions for precision resistors for current sensing and fuses, continuously enhancing its core competitiveness, and contributing to the transformation and upgrade of China's manufacturing industry and high-quality development. Currently, China's manufacturing industry is entering a new stage of transitioning from high-speed development to high-quality development. Strengthening independent innovation in core technologies and actively guiding small and medium-sized enterprises towards specialized, refined, distinctive, and innovative development is gradually becoming an important aspect of the development of the electronic information industry. Huatai United Securities always adheres to the national development strategy, closely follows the "Five Major Financial Articles" for financial work, and focuses on serving the development of new productive forces at the forefront of science and technology. The listing of Junwei Electronics is another example of Huatai United Securities serving the national strategy and promoting self-reliance in science and technology. In the future, Huatai United Securities will steadfastly serve the needs of the country and contribute financial strength to self-reliance in science and technology and independent control in key areas.

10/01/2025

Unisplendour Corporation (000938.SZ) is considering listing in Hong Kong and plans to raise $1 billion in funding.

Recently, there have been reports that Unisplendour Corporation (000938.SZ) is considering a secondary listing in Hong Kong, with a possible fundraising amount of 1 billion US dollars. The company's main business is in the computer industry, with a focus on scanners and software development and sales. Unisplendour Corporation has leading digital technology and a full range of key hardware and software products needed for the construction of next-generation information infrastructure. Faced with the opportunities brought by the integration trend of new digital technologies represented by cloud computing, big data, artificial intelligence, and 5G, as well as the deepening development of the digital economy, the company will continue to adhere to innovation-driven development and continuously enhance its core competitiveness. According to the latest data released by IDC, in the first quarter of 2024, the company's market share in various products continued to lead. The company ranks first in the Chinese Ethernet switch, enterprise network switch, and park switch markets with market shares of 34.8%, 36.5%, and 41.6% respectively. In the Chinese data center switch market, it holds a 29.0% market share, ranking second. In the Chinese enterprise network router market, it holds a 30.7% market share, ranking second. In the Chinese enterprise WLAN market, it holds a 30.3% market share, ranking first. In the Chinese X86 server market, it holds a 15.6% market share, maintaining second place. In the Chinese UTM firewall market, it holds a 22.9% market share, ranking second.

09/01/2025

Chongqing Sokon Industry Group Stock has been awarded the title of "Best Listed Company" by 2024 New Fortune, continuing to break records in the luxury car market.

On January 6, 2024, the "New Fortune" magazine announced the list of the best listed companies. Chongqing Sokon Industry Group Stock was awarded the title of "Best Listed Company" for its outstanding development performance and brand influence. The selection of the best listed companies by "New Fortune" aims to comprehensively evaluate the quality of information disclosure, ESG practices, brand strength, etc. of listed companies, to find typical representatives who are most recognized in terms of integrity, sustainable development, and national brand, and to promote their experience to build a good environment in the capital market. Data shows that in 2024, Chongqing Sokon Industry Group Stock sold 426,885 new energy vehicles throughout the year, a year-on-year increase of 182.84%; achieved operating income of 106.627 billion yuan in the first three quarters, a year-on-year increase of 539.24%, and a net profit attributable to the shareholders of the listed company of 4.038 billion yuan. It was also in this year that Chongqing Sokon Industry Group Stock became the fourth new energy vehicle company in the world to achieve profitability. With the continuous growth of the company's scale and efficiency, Chongqing Sokon Industry Group Stock has been included in the four major indexes of the Shanghai and Shenzhen 300, Shanghai 50, CSI A500, and Shanghai 180, and has received "strongly recommended," "outperforming the market," "buy" and other ratings from securities firms such as EB SECURITIES, CICC, Founder, CITIC SEC, and Ping An Securities. At the same time, the joint venture "Wenjie" created by Chongqing Sokon Industry Group Stock and Huawei is increasingly recognized and favored by the industry and users. A report released by professional consulting firm Jilanlu shows that in 2024, Wenjie was awarded the double first in Brand Net Promoter Score (NPS) and Brand Development Confidence Index. In 2024, Wenjie's new M7 delivered a total of 200,000 new cars, won the annual sales crown of new energy brands in 2024, and set a new record for luxury brands in Shanxi Guoxin Energy Corporation; while Wenjie's M9, as a panoramic intelligent flagship SUV, achieved a cumulative sales of over 200,000 units in just one year since its launch, and has been the sales champion of the Chinese market for luxury vehicles priced at 500,000 yuan and above for 9 consecutive months.

07/01/2025

The next stop of technological evolution? Beijing Roborock Technology (688169.SH) prepares for CES 2025 with new products.

As the 2025 Consumer Electronics Show (CES) in the United States approaches, major technology companies are gearing up. The CES 2025 exhibition will be held in Las Vegas, USA from January 7th to 10th, attracting top global brands to participate. It is reported that this year's exhibition will have more than 3,300 companies from 50 countries/regions participating, including household appliance companies such as Hisense, TCL, and Beijing Roborock Technology (688169.SH). The products will cover AI, electric travel, smart homes, VR/AR, and many other fields. Beijing Roborock Technology (Roborock) has attracted industry attention ahead of the exhibition, with information from overseas social media Reddit indicating that Beijing Roborock Technology will launch a new flagship product - the Saros Z70 at this year's CES 2025 exhibition. As a leader in the global sweeping Siasun Robot&Automation industry, Beijing Roborock Technology's new move heralds a new wave of upgrades in smart home technology. Breaking through the two-dimensional: the "cross-dimensional" upgrade of sweeping Siasun Robot&Automation It is reported that this year's CES 2025 covers multiple cutting-edge fields such as artificial intelligence (AI), electric travel, smart homes, and VR/AR. Especially in the smart home sector, the deep integration of automation equipment and artificial intelligence technology has become the core trend of market attention. Various tech companies set to participate have all hinted at launching new smart home products at the exhibition, showcasing the application of various cutting-edge technologies in home scenarios. Beijing Roborock Technology, as a global leader in the sweeping Siasun Robot&Automation field, has been focusing on technological breakthroughs and product innovation for many years. Their participation in this year's exhibition is bound to have a significant impact on the future development of the industry. According to Reddit information, the new Saros Z70 product from Beijing Roborock Technology will introduce revolutionary technology, marking a comprehensive evolution of sweeping Siasun Robot&Automation products from traditional "two-dimensional cleaning" to "three-dimensional operation". Industry experts estimate that this technological upgrade will not only allow the sweeping robot to break through the limitations of floor cleaning but also open up more application scenarios in the home environment. While specific features and technical details have not been fully disclosed, this change in product form has become a focal point of industry and user attention. Guotai Junan Securities also stated that there is a catfish effect in the industry, and more players will follow suit. Beijing Roborock Technology's new product marks the entry of sweeping Siasun Robot&Automation products into the application of a three-dimensional space from two dimensions, also connecting them more closely with artificial intelligence as a smart home assistant. It is expected that more players will join in the future. On one hand, the launch of new iterations by Beijing Roborock Technology will further promote the industry towards more intelligent product forms, and on the other hand, various manufacturers in the industry will also conduct more attempts around product cost reduction to accelerate the mass production of products. New trends in smart homes: catalyst for industry innovation Looking at the development of sweeping Siasun Robot&Automation, products have evolved from initially random cleaning to planned cleaning, and then to the era of full automation with the introduction of base stations. In 1996, Electrolux launched the first sweeping Siasun Robot&Automation, laying the foundation for the industry. In 2004, iRobot introduced cleaning planning to enhance intelligence, launching the Roomba 980 in 2015, marking a revolutionary breakthrough in performance. By 2016, Beijing Roborock Technology used LDS technology to lower the consumer threshold, enabling sweeping Siasun Robot&Automation to make a qualitative leap, truly entering the era of intelligence and achieving substantial popularization of sweeping Siasun Robot&Automation. Starting in 2019, Beijing Roborock Technology has led the industry into the era of base stations, achieving convenient functions such as self-cleaning and self-dust collection, gradually moving towards a smart life that frees hands. The new product release from Beijing Roborock Technology at CES 2025 will further raise the industry's technological threshold and bring consumers a more intelligent and efficient home service experience. Official information for CES 2025 shows that the deep integration of artificial intelligence and smart hardware is an important theme, with many companies showcasing smarter and more convenient home solutions. It is not difficult to imagine that the innovation Beijing Roborock Technology is about to bring is not just a simple product upgrade, but a leading attempt at a crucial point in the industry's development. In recent years, competition in the smart home market has become increasingly fierce, with major brands stepping up their technology research and development to drive product iteration. It is worth noting that as technology advances and consumer demands diversify, the future sweeping Siasun Robot&Automation will gradually transform into an important node in the smart home ecosystem. More intelligent devices with higher-dimensional interaction capabilities will gradually integrate into home scenarios, providing users with life experiences beyond expectations. Judging from the product trends introduced by major companies at this year's CES, it is not difficult to predict that 2025 will be a key year for the "cross-dimensional evolution" of smart home technology.

06/01/2025

Joining the ranks of the world's top medical technology countries! Beijing Wandong Medical Technology (600055.SH) is well-known on the DSA list.

At the time of the vigorous development of the medical and health care industry in our country, the independent innovation and promotion application of high-end medical equipment have become a key link. Recently, the National Health Commission released the "2024 High-end Medical Equipment Promotion Application Project Publicity", and the CGO-5200 series DSA products independently developed and produced by Beijing Wandong Medical Technology under the Midea Medical sector were successfully selected for their outstanding innovation and leading technology. It is reported that the high-end medical equipment promotion application project is a joint project carried out by the Office of the Ministry of Industry and Information Technology of China and the Office of the National Health Commission, aiming to further implement the "Healthy China" and "Manufacturing Strong Country" strategies, accelerate the innovative development and promotion application of high-end medical equipment in accordance with the deployment requirements of the "14th Five-Year Plan" for the development of the medical equipment industry. The project targets typical application scenarios, mainly selecting projects that are at the forefront of the country in terms of technological innovation and clinical application levels of high-end medical equipment, and have a strong leading role in promoting synergy innovation between medical and engineering, pilot verification, clinical research, iterative upgrade, and promotion and application. According to the person in charge of Beijing Wandong Medical Technology, the selected CGO-5200 series not only meets all four requirements of the Ministry of Industry and Information Technology and the Health Commission, but also achieves breakthroughs and advancements in both technological innovation and clinical application. The hardware uses industry-leading ultra-dynamic flat-panel detectors and large heat capacity ball tubes to continuously optimize and improve image quality; software-wise, the CGO-5200Pro incorporates cutting-edge artificial intelligence technology, deep learning, intelligent noise reduction, and fusion post-processing technology to achieve precise low-dose imaging. Innovative research and development of dual-axis acquisition, stent enhancement, 3D imaging, InvaRayCT, and other advanced functions provide a series of solutions for vascular and non-vascular intervention surgeries in the nervous system, peripheral, tumor, heart, and other areas, meeting the national requirements for intelligent and precise high-end medical equipment. Wandong stated that the selection this time is inseparable from the company's continuous innovation and deep R&D accumulation. Especially after joining Midea Group Co., Ltd, the company's R&D strength and capabilities have rapidly improved, co-innovating with Midea Central Research Institute and Midea AI Research Institute, focusing on medium-to-long-term common technologies, forward-looking technology research, and disruptive product platform innovation, further consolidating the company's innovation foundation, and successively launching multiple original research and development products. In the future, under the strategic guidance of "product leadership, data intelligence-driven", Beijing Wandong Medical Technology will continue to innovate breakthroughs, continuously promote the empowerment of state-owned high-end equipment for precise clinical applications, and inject majestic power into the "Healthy China" initiative.

30/12/2024

Breakthrough and Metaphor of Contemporary Amperex Technology's Listing in Hong Kong

Starting from 2023, there have been widespread rumors in the market about Contemporary Amperex Technology (300750.SZ) listing in Hong Kong, and now the rumors have finally come true. On December 27, Contemporary Amperex Technology officially announced its listing in Hong Kong. Although the fundraising amount has not been disclosed, according to media reports, the amount raised may be around $5 billion, with the corresponding H-share issuance ratio at about 3%. According to the rules of the Hong Kong Stock Exchange, the public shareholding ratio of a listed company's stock cannot be lower than 25%, but exemptions can be granted in special circumstances. However, based on past practices, the H-share issuance ratio of A-share companies is usually not less than 5%. However, this year, S.F. Holding (06936) became the first A-share company to have an H-share issuance ratio lower than 5% when it listed on the Hong Kong Stock Exchange. This may be the underlying logic behind the rumored fundraising amount for Contemporary Amperex Technology, and it is expected to relieve some of the fundraising pressure for its H-share issuance. Contemporary Amperex Technology still has substantial cash reserves, with cash and cash equivalents amounting to 234.954 billion yuan at the end of the third quarter of this year. However, at the same time, there are challenges in terms of the foreign exchange reserves needed for international expansion. As of the end of June this year, the balances in US dollars and euros were 6.735 billion yuan and 3.858 billion yuan respectively. Regarding the necessity of listing in Hong Kong, Contemporary Amperex Technology stated that it is to "advance its global strategy and build an international capital operation platform." "Less than 5%" - the second case? Contemporary Amperex Technology's listing in Hong Kong this time did not exceed market expectations. Earlier, media reports had stated that Contemporary Amperex Technology planned to list in Hong Kong, but at the time, it did not deny this. Currently, Contemporary Amperex Technology has not disclosed the fundraising amount. According to previous reports, Contemporary Amperex Technology planned to raise $5 billion, which is equivalent to about 36.5 billion yuan, and the corresponding H-share issuance ratio is estimated to be 3.2%, but this information has not been confirmed by Contemporary Amperex Technology. In fact, the back-calculated issuance ratio is related to the changes in actual cases of H-share issuances on the Hong Kong Stock Exchange. According to the listing rules of the Hong Kong Stock Exchange, the total number of issued shares (excluding treasury shares) must be at least 25% held by the public, but exemptions can be applied for in special circumstances. According to TradeWind01, citing sources close to investment banks working with the Hong Kong Stock Exchange, the A-share company Midea Group Co., Ltd (00300), which listed on the Hong Kong Stock Exchange this year, applied for an exemption, resulting in an H-share issuance ratio of 7.49%. For a long time, the issuance ratio was generally not less than 5%, but this year, S.F. Holding's issuance broke this potential constraint, with an H-share issuance ratio as low as 3.41%, becoming the first A-share company to have an issuance ratio exceeding 5%. "In the practical process, A-share companies generally communicate and agree on an H-share issuance ratio above 5%, but with SF Express breaking this limit, and now encouraging A-share companies to list in Hong Kong, the issuance ratio for large-cap companies may be further relaxed in the future," said an investment bank executive in Beijing. This may further reduce the fundraising pressure for Contemporary Amperex Technology. According to TradeWind01, based on a 5% H-share issuance ratio, the fundraising amount for Contemporary Amperex Technology could reach 57.6 billion yuan, potentially making it the fourth largest fundraising scale in the history of the Hong Kong Stock Exchange in the past decade. However, some market participants believe that in order to reduce the dilution impact on equity, Contemporary Amperex Technology's issuance ratio could be lower than 5%. If calculated based on a 3%-4% H-share issuance ratio, the fundraising amount for Contemporary Amperex Technology would be between 34.5 billion yuan and 46 billion yuan. This means that if Contemporary Amperex Technology can issue shares at this ratio, it may become the second A-share company after SF Express to have an H-share issuance ratio of less than 5%. These are all speculations, and the final fundraising amount for Contemporary Amperex Technology may not necessarily be limited to $5 billion. An example of unexpected exceedance was the previous listing of Midea Group Co., Ltd in Hong Kong. Before listing in Hong Kong, the South China Morning Post had stated that its fundraising amount was $1 billion, but the final fundraising amount reached $4.5 billion. Aiming for global "ammunition" Contemporary Amperex Technology is "not short of money." As of the end of the third quarter of this year, Contemporary Amperex Technology had cash and cash equivalents of 234.954 billion yuan. As early as 2022, Contemporary Amperex Technology had raised 45 billion yuan for projects such as lithium-ion battery production bases. As of the end of June this year, Contemporary Amperex Technology...The amount of funds raised that has not been used yet still reaches 9.312 billion yuan, of which 6.437 billion yuan has been used for cash management.In fact, perhaps the foreign exchange is the most urgent gap to be filled. As of the end of June this year, Contemporary Amperex Technology had foreign currency balances of $6.735 billion and 3.858 billion. Such foreign currency reserves may pose certain pressures for Contemporary Amperex Technology, which is building factories overseas. In December of this year, Contemporary Amperex Technology announced plans to jointly establish a joint venture company in Spain with Stellantis, the fourth largest global car manufacturer. Both parties will hold a 50% stake in the joint venture company to build a joint battery factory in Zaragoza, Aragon Autonomous Community, Spain, with an expected total investment of up to 4.038 billion. According to the 50% ownership ratio, Contemporary Amperex Technology needs to invest at least 2.919 billion. Meanwhile, the first phase of Contemporary Amperex Technology's factory in Hungary is still under construction. With more overseas expansion, the demand for foreign exchange by Contemporary Amperex Technology is also gradually increasing, but its overseas income proportion is relatively limited. In the first half of 2024, Contemporary Amperex Technology's overseas income was 50.529 billion, accounting for around 30% of total income. As the domestic market competition intensifies, going global is indeed an important way for Contemporary Amperex Technology to open up performance space, but the growth of the new energy vehicle market in Europe is not significant. According to Dataforce data, the sales of pure electric vehicles in Europe decreased by 0.4% year-on-year in November, with a 1.4% decrease in sales from January to November this year. In November, the European Automobile Manufacturers Association lowered the market share of pure electric vehicles in 2025 from the beginning of the year's 27% to 21%. As a partner of Contemporary Amperex Technology, Stellantis is also having a tough time, with revenue and net profit in the first half of 2024 decreasing by 13.57% and 48.51%, respectively. This may bring greater pressure to the internationalization of Contemporary Amperex Technology. Policy support is frequent In addition to Contemporary Amperex Technology, A-share companies such as "pharmaceutical leader" Jiangsu Hengrui Pharmaceuticals (600276.SH), semiconductor company Shenzhen Longsys Electronics (301308.SZ), and Fortior Technology (Shenzhen) Co., (688279.SH) are planning to go public in Hong Kong to further open up overseas markets. This is also inseparable from the strong support of the regulatory authorities. On the one hand, to promote A-share companies' financing through listing in Hong Kong, the Hong Kong Stock Exchange recently planned to further lower the listing threshold. The Hong Kong Stock Exchange suggested lowering the minimum threshold for A+H-share issuers to list in Hong Kong to at least 10% of the total issued shares of the same category of A+H-share issuers (excluding treasury shares), or the expected market value of the relevant H-shares at the time of listing is at least HK$3 billion and held by the public. Compared to the 25% H-share issuance ratio, this has already been significantly reduced. "A high H-share issuance ratio will bring more pressure to companies with higher market capitalization because they may not be able to raise such a large amount," a banker in Shanghai pointed out. For example, without considering exemptions and other conditions, if an A-share company has a market value of 5 billion, according to the past 25% issuance proportion, it needs to raise 1.25 billion; but if the company's market value is 50 billion, the fundraising size needs to reach 12.5 billion. If the Hong Kong Stock Exchanges suggestions are implemented, the Hong Kong fundraising pressure for A-share companies will also be further reduced. On the other hand, the China Securities Regulatory Commission has been continuously supporting domestic companies to list in Hong Kong. In April of this year, the China Securities Regulatory Commission issued a document stating that it will further increase communication and coordination with relevant departments to support qualified leading domestic enterprises to raise funds through listing in Hong Kong. "Previously, some A-share companies with relatively high market capitalization wanted to list in Hong Kong, and they needed to communicate with domestic regulatory agencies for a long time because relevant departments were concerned about the impact on domestic market prices," a banker in East China pointed out, "But the current policy still supports A-share companies to list in Hong Kong, and the Hong Kong Stock Exchange and Hong Kong regulatory agencies are very cooperative." However, the banker also admitted that Hong Kong fundraising is more market-oriented and pricing of the company's issuance is also a test. "Although the threshold will be further lowered, the main problem with Hong Kong fundraising is that it is more difficult to issue, and cornerstone investments and follow-up trades require money. Leading companies may be better off, but companies with average market recognition may still face difficulties in fundraising," the aforementioned banker further pointed out. This article is compiled from "Wall Street See". Editor: Zhang Jinliang.

28/12/2024

Contact: contact@gmteight.com